D
Dave Morgan
Researcher at University of South Florida
Publications - 114
Citations - 17627
Dave Morgan is an academic researcher from University of South Florida. The author has contributed to research in topics: Amyloid precursor protein & Amyloid. The author has an hindex of 51, co-authored 112 publications receiving 14471 citations. Previous affiliations of Dave Morgan include University of Southern California.
Papers
More filters
Journal ArticleDOI
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more
TL;DR: Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction.
Journal ArticleDOI
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.
Dave Morgan,David M. Diamond,Paul E. Gottschall,Kenneth E. Ugen,Chad A. Dickey,John Hardy,Karen Duff,Paul T. Jantzen,Giovanni DiCarlo,Donna M. Wilcock,Karen E. Connor,Jaime M. Hatcher,Caroline Hope,Marcia N. Gordon,Gary W. Arendash +14 more
TL;DR: It is shown that vaccination with Aβ protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease and may prevent and, possibly, treat Alzheimer's dementia.
Journal ArticleDOI
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj Linda B. Selenica,Milene Brownlow,Jeffy Jimenez,Daniel C. Lee,Gabriela Pena,Chad A. Dickey,Marcia N. Gordon,Dave Morgan +7 more
TL;DR: The data suggest that even brief elevations in Aβ production, may have enduring impact on the risk for tauopathy, and Soluble Aβ1-42 oligomers have long-lasting effects on tau phosphorylation in the rTg4510 model.
Journal ArticleDOI
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
Leigh A. Holcomb,Marcia N. Gordon,Eileen McGowan,Xin Yu,Stan Benkovic,Paul T. Jantzen,Kristal Wright,Irene Saad,Ryan Mueller,Dave Morgan,Sunny Sanders,Cindy Zehr,Kassandra O'Campo,John Hardy,Cristian Mihail Prada,Chris Eckman,Steven G. Younkin,Karen Hsiao,Karen Duff +18 more
TL;DR: The development of AD-like pathology is substantially enhanced when a P51 mutation, which causes a modest increase in Aβ42(43), is introduced into Tg2576-derived mice, and both doubly and singly transgenic mice showed reduced spontaneous alternation performance in a “Y” maze before substantial Aβ deposition was apparent.
Journal ArticleDOI
Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage
Donna M. Wilcock,Amyn M. Rojiani,Arnon Rosenthal,Sangeetha Subbarao,Melissa J. Freeman,Marcia N. Gordon,Dave Morgan +6 more
TL;DR: The cognitive benefits of passive immunotherapy persist in spite of the presence of vascular amyloid and small hemorrhages, and these data suggest that clinical trials evaluating such treatments will require precautions to minimize potential adverse events associated with microhemorrhage.